Aurobindo Pharma Ltd vs Kopran Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 14, 2026

Key Highlights

The Latest Trading Price of Aurobindo Pharma Ltd is ₹ 1472 as of 12 Jun 15:30 . The P/E Ratio of Aurobindo Pharma Ltd changed from 9.7 on March 2021 to 19.3 on March 2025 . This represents a CAGR of 14.75% over 5 yearsThe P/E Ratio of Kopran Ltd changed from 7.4 on March 2021 to 21.9 on March 2025 . This represents a CAGR of 24.23% over 5 years The Market Cap of Aurobindo Pharma Ltd changed from ₹ 51653 crore on March 2021 to ₹ 67951 crore on March 2025 . This represents a CAGR of 5.64% over 5 yearsThe Market Cap of Kopran Ltd changed from ₹ 453.94 crore on March 2021 to ₹ 845.48 crore on March 2025 . This represents a CAGR of 13.25% over 5 years The revenue of Aurobindo Pharma Ltd for the Mar '26 is ₹ 8970 crore as compare to the Dec '25 revenue of ₹ 8833 crore. This represent the growth of 1.54% The revenue of Kopran Ltd for the Mar '26 is ₹ 234.11 crore as compare to the Dec '25 revenue of ₹ 194.35 crore. This represent the growth of 20.46% The ebitda of Aurobindo Pharma Ltd for the Mar '26 is ₹ 1867 crore as compare to the Dec '25 ebitda of ₹ 1896 crore. This represent the decline of -1.51% The ebitda of Kopran Ltd for the Mar '26 is ₹ 33.04 crore as compare to the Dec '25 ebitda of ₹ 17.83 crore. This represent the growth of 85.31% The net profit of Aurobindo Pharma Ltd changed from ₹ 918.22 crore to ₹ 920.84 crore over 8 quarters. This represents a CAGR of 0.14% The net profit of Kopran Ltd changed from ₹ 11.1 crore to ₹ 18.87 crore over 8 quarters. This represents a CAGR of 30.38% The Dividend Payout of Aurobindo Pharma Ltd changed from 7.53 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Kopran Ltd changed from 55.28 % on March 2021 to 53.94 % on March 2025 . This represents a CAGR of -0.49% over 5 years .

About Aurobindo Pharma Ltd

Aurobindo Pharma Limited (APL), one of the world's top 5 manufacturers of semi synthetic penicillins was incorporated in December 1986 as a private limited company.
Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a small, highly committed group of professionals founded it.
APL is developing, manufacturing and marketing active pharmaceutical ingredients (APIs also referred as bulk actives), intermediates and generic formulations.
The company's robust product portfolio is spread over 6 major product areas encompassing (Antibiotics, Anti-Retro Virals, CVS, CNS, Gastroenterologicals, and Anti-Allergics) with around 65 APIs in the non-antibiotics and over 55 APIs in the antibiotic segment and the World Health Organization (WHO), Geneva, has also approved Aurobindo's products.
APL is running with 29 manufacturing plants across the world conforming to GMP/ISO regulations and an extremely well equipped 9 R&D facilities.

About Kopran Ltd

Kopran Limited, incorporated on April 26, 1958, was promoted by the Somani group and is a group company of Parijat Enterprises.
Company operates in two distinct business verticals.
While pharmaceutical formulations production is managed by Kopran Limited, manufacturing of API is operated under Kopran Research Laboratories Limited (KRLL).
Company specialise in developing and manufacturing Penicillin and non-penicillin-based drugs.
Leveraging cutting-edge technology, it manufactures highquality finished dosage drugs that adhere to international requirements.

FAQs for the comparison of Aurobindo Pharma Ltd and Kopran Ltd

Which company has a larger market capitalization, Aurobindo Pharma Ltd or Kopran Ltd?

Market cap of Aurobindo Pharma Ltd is 85,508 Cr while Market cap of Kopran Ltd is 875 Cr

What are the key factors driving the stock performance of Aurobindo Pharma Ltd and Kopran Ltd?

The stock performance of Aurobindo Pharma Ltd and Kopran Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aurobindo Pharma Ltd and Kopran Ltd?

As of June 14, 2026, the Aurobindo Pharma Ltd stock price is INR ₹1472.25. On the other hand, Kopran Ltd stock price is INR ₹181.35.

How do dividend payouts of Aurobindo Pharma Ltd and Kopran Ltd compare?

To compare the dividend payouts of Aurobindo Pharma Ltd and Kopran Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.